The nitric oxide-independent soluble guanylate cyclase activator ataciguat continued to show promise for slowing the ...

If validated prospectively, the findings could be ‘transformative’ for patients with no current medical options.

Ataciguat, a new drug being studied for aortic valve stenosis, shows promise in slowing disease progression and reducing the ...

The phase II data are promising for patients who are managed with watchful waiting before being offered an intervention.

Fibrosis predicts post-surgical risk in aortic stenosis, reinforcing its role in guiding treatment decisions for both sexes.

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally.

Pi-Cardia Inc., a global leader in the development of leaflet modification solutions for treating heart valves, announced today the first commercial procedures with ShortCut™ - the world's first ...

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally. Researchers are exploring the use of a new drug called ataciguat to manage ...

An experimental drug, ataciguat, initially created by Sanofi and further developed by the Mayo Clinic, has significantly ...

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally.

The collaboration aims to upskill over 300 cardiologists and radiologists in echocardiography and MRI, with a focus on ...